ASD
MCID: ATS007
MIFTS: 65

Autism Spectrum Disorder (ASD) malady

Categories: Genetic diseases, Rare diseases, Mental diseases

Aliases & Classifications for Autism Spectrum Disorder

About this section

Aliases & Descriptions for Autism Spectrum Disorder:

Name: Autism Spectrum Disorder 11 48 49 38 13
Autism Spectrum Disorders 24 27 68
Pervasive Development Disorder 68
 
Pdds 24
Asd 48

Classifications:



External Ids:

Disease Ontology11 DOID:0060041

Summaries for Autism Spectrum Disorder

About this section
MedlinePlus:38 Autism spectrum disorder (asd) is a neurological and developmental disorder that begins early in childhood and lasts throughout a person's life. it affects how a person acts and interacts with others, communicates, and learns. it includes what used to be known as asperger syndrome and pervasive developmental disorders. it is called a "spectrum" disorder because people with asd can have a range of symptoms. people with asd might have problems talking with you, or they might not look you in the eye when you talk to them. they may also have restricted interests and repetitive behaviors. they may spend a lot of time putting things in order, or they may say the same sentence again and again. they may often seem to be in their "own world." at well-child checkups, the health care provider should check your child's development. if there are signs of asd, your child will have a comprehensive evaluation. it may include a team of specialists, doing various tests and evaluations to make a diagnosis. the causes of asd are not known. research suggests that both genes and environment play important roles. there is currently no one standard treatment for asd. there are many ways to increase your child's ability to grow and learn new skills. starting them early can lead to better results. treatments include behavior and communication therapies, skills training, and medicines to control symptoms. nih: national institute of child health and human development

MalaCards based summary: Autism Spectrum Disorder, also known as autism spectrum disorders, is related to adnp-related intellectual disability and autism spectrum disorder and autism spectrum disorder susceptibility, chd8-related, and has symptoms including widespread abnormalities of social interactions, severely restricted interests and highly repetitive behavior. An important gene associated with Autism Spectrum Disorder is EHMT1 (Euchromatic Histone Lysine Methyltransferase 1), and among its related pathways are Muscular Dystrophies and Dystrophin-Glycoprotein Complex and Protein-protein interactions at synapses. Affiliated tissues include brain, eye and testes, and related mouse phenotypes are behavior/neurological and growth/size/body region.

NIH Rare Diseases:48 Autism spectrum disorder (asd) is a condition that affects the development of social and communication skills. it includes features of four conditions which were once thought to be separate syndromes - autistic disorder, asperger syndrome, childhood disintegrative disorder, and pervasive developmental disorder. signs and symptoms often become apparent in the first 2-3 years of life and vary significantly from person to person. common symptoms shared by people with asd include restrictive and repetitive behaviors, social impairment and communication difficulties. the underlying cause of asd is generally unknown and it is likely that a variety of factors contribute to the development of the condition. asd appears to run in some families, suggesting that genetics may play a role in some cases. although there is no cure for asd, treatment is available that significantly improves the long-term outlook for affected people. treatment often includes a combination of techniques such as medications, occupational therapy, speech therapy and physical therapy. last updated: 12/1/2016

NINDS:49 Autistic disorder (sometimes called autism or classical ASD) is the most common condition in a group of developmental disorders known as the autism spectrum disorders (ASDs).

Disease Ontology:11 A pervasive developmental disorder that is a spectrum of psychological conditions. The disease has symptom widespread abnormalities of social interactions and communication, has symptom severely restricted interests and has symptom highly repetitive behavior.

Wikipedia:71 Autism spectrum describes a range of conditions classified as neurodevelopmental disorders in the DSM-5,... more...

Related Diseases for Autism Spectrum Disorder

About this section

Diseases in the Autism Spectrum Disorder family:

Autism 19 Autism 9
Autism 10 Autism 18

Diseases related to Autism Spectrum Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 156)
idRelated DiseaseScoreTop Affiliating Genes
1adnp-related intellectual disability and autism spectrum disorder12.2
2autism spectrum disorder susceptibility, chd8-related12.0
3autism spectrum disorder susceptibility, kmt5b-related12.0
4intellectual disability and/or autism spectrum disorder, ash1l-related12.0
5patent foramen ovale11.8
6adnp syndrome11.7
7arthrogryposis, mental retardation, and seizures11.5
8helsmoortel-van der aa syndrome11.5
9asperger syndrome11.5
10pervasive developmental disorder11.3
11fragile x syndrome11.2
12rett syndrome11.1
13specific language impairment11.1
14chromosome 15q13.3 microdeletion syndrome11.1
1516p11.2 duplication11.1
16mental retardation, autosomal dominant 2611.0
17mental retardation, autosomal recessive 3811.0
18specific language impairment 510.9
19timothy syndrome10.9
20chromosome 15q11.2 deletion syndrome10.9
21epilepsy, familial focal, with variable foci10.9
22autism x-linked 410.9
23atypical autism10.9
24childhood disintegrative disease10.9
25syngap1-related intellectual disability10.9
26chromosome 2q37 deletion syndrome10.8
27autism susceptibility 1610.8
28athabaskan brainstem dysgenesis syndrome10.8
29autism 910.8
30autism susceptibility 1510.8
31autism 1010.8
32macrocephaly/autism syndrome10.8
33autism susceptibility 1710.8
34autism 1810.8
35schaaf-yang syndrome10.8
36chromosome 16p13.3 duplication syndrome10.8
37potocki-lupski syndrome10.8
38autism susceptibility, x-linked 210.8
39autism susceptibility, x-linked 110.8
40autism susceptibility, x-linked 310.8
41autism x-linked 510.8
42epsilon-trimethyllysine hydroxylase deficiency10.8
43speech and communication disorders10.8
44autistic disorder10.8
45chromosome 1q21.1 deletion syndrome10.8
4647,xyy syndrome10.8
47cask-related disorders10.8
4816p11.2 deletion syndrome10.8
4916q24.3 microdeletion syndrome10.8
50autosomal dominant intellectual disability 3010.8

Graphical network of the top 20 diseases related to Autism Spectrum Disorder:



Diseases related to autism spectrum disorder

Symptoms & Phenotypes for Autism Spectrum Disorder

About this section

Symptoms:

 11
  • widespread abnormalities of social interactions
  • severely restricted interests
  • highly repetitive behavior

MGI Mouse Phenotypes related to Autism Spectrum Disorder according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538611.1AUTS2, CNTNAP2, EHMT1, FMR1, MECP2, NLGN3
2MP:000537811.1AUTS2, CNTNAP2, EHMT1, FMR1, MECP2, NLGN3
3MP:000363110.3CNTNAP2, EHMT1, FMR1, MECP2, NLGN3, NRXN1

Drugs & Therapeutics for Autism Spectrum Disorder

About this section

Drugs for Autism Spectrum Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 331)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Methylphenidateapproved, investigationalPhase 4, Phase 2, Phase 3375113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
 
Methyl phenidyl acetate
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
2
Memantineapproved, investigationalPhase 4, Phase 3, Phase 2, Early Phase 118119982-08-24054
Synonyms:
1,3-Dimethyl-5-adamantanamine
1-Amino-3,5-dimethyladamantane
19982-08-2
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-adamantylamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyladamantan-1-ylamine
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyladamantan-1-amine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
41100-52-1 (Hydrochloride)
51052-62-1
AB00053600
AC1L1HB7
AKOS000113995
BBL000737
BPBio1_001117
BPBio1_001270
BSPBio_001015
Biomol-NT_000209
C13736
CBMicro_020348
CHEBI:152523
CHEMBL807
CID4054
D08174
DB01043
DMAA
DivK1c_000068
EU-0053634
Ebixa
Exiba
Exiba (TN)
HMS500D10
HSDB 7327
IDI1_000068
KBio1_000068
KBio2_001087
KBio2_003655
 
KBio2_006223
KBio3_001926
KBioGR_001543
KBioSS_001087
LS-157051
Lopac0_000861
Memantin
Memantina
Memantina [INN-Spanish]
Memantine
Memantine (INN)
Memantine HCL
Memantine Hydrochloride
Memantine [INN:BAN]
Memantine [INN]
Memantinum
Memantinum [INN-Latin]
MolPort-002-041-858
NCGC00015705-05
NCGC00024782-02
NCGC00024782-03
NINDS_000068
Namenda
Oprea1_480562
Prestwick0_000978
Prestwick1_000978
Prestwick2_000978
Prestwick3_000978
SPBio_001456
SPBio_002926
ST057652
STK520682
Spectrum2_001408
Spectrum3_000923
Spectrum4_001022
Spectrum5_001355
Spectrum_000607
UNII-W8O17SJF3T
ZERO/006024
memantine
3
DopamineapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
4
Oxytocinapproved, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 143950-56-6439302, 53477758
Synonyms:
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
(Arg8)-Vasopressin
(Arg8)-Vasotocin
1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide
50-56-6
AC1L9735
Argipressin
Argpressin Acetate
BCBcMAP01_000094
Biotinyl-(Arg8)-Vasopressin
C00746
CHEBI:492195
CHEBI:7872
CHEMBL395429
CID439302
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
Cys-Tyr-Ile-Thr-Asn-Cys-Gly-Leu-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2
D00089
Disulfide bridge Cys1-Cys6
Gly-Leu-Pro-c
HS-2021
 
L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide
MolPort-003-938-941
NCGC00167132-01
O3251_SIGMA
O4375_SIGMA
OXT
OXYTOCIN
Ocytocin
Oxitocina
Oxytocic hormone
Oxytocin (JP15/USP/INN)
Oxytocin (TN)
Oxytocin 10 Usp Units In Dextrose 5%
Oxytocin 20 Usp Units In Dextrose 5%
Oxytocin 5 Usp Units In Dextrose 5%
Oxytocin Acetate
Oxytocin injection
Oxytocine
Oxytocinum
Pitocin
Pitocin (TN)
Syntocinon
Syntocinon (TN)
TI-001
alpha-Hypophamine
nchembio.184-comp2
5
Aripiprazoleapproved, investigationalPhase 4, Phase 3, Phase 2358129722-12-960795
Synonyms:
129722-12-9
24-29-3
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
AC-1554
AC1L1TXZ
AC1Q3T38
ALKS-9070
Abilify
Abilify (TN)
Abilify Discmelt
Abilitat
Aripiprazol
Aripiprazole
Aripiprazole (JAN/USAN/INN)
Aripiprazole [USAN]
Aripiprazolum
Aripirazole
Arpizol
Asprito|
BMS-337039
Bio-0004
Bristol-Myers Squibb brand of aripiprazole
C094645
C12564
C23H27Cl2N3O2
CHEBI:31236
CHEMBL1112
CID60795
CPD000466383
 
D01164
DB01238
Discmelt
FT-0082572
HMS2051I18
HMS2089M20
HMS2093F22
HSDB 7320
KS-1030
L001339
LS-142666
MLS000759517
MLS001165779
MLS001195621
MLS001424078
MolPort-002-885-808
MolPort-003-844-657
NCGC00159510-02
NCGC00159510-03
OPC 31
OPC-14597
OPC-31
Opc 14597
Otsuka brand of aripiprazole
Pripiprazole
S06-0010
SAM001246750
SMR000466383
STK625160
TL8000707
TL80090184
UNII-82VFR53I78
aripiprazol
aripiprazole
aripiprazolum
||OPC 14597
6
MilnacipranapprovedPhase 45992623-85-365833
Synonyms:
( -)-Milnacipran
(+-)-cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
(-)-milnacipran
(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane HCl
105310-09-6
92623-85-3
AC1L2425
CHEMBL252923
CID65833
D08222
DB04896
F 2207
 
F-2207
F2207
Ixel
LS-178180
Midalcipran
Milnacipran
Milnacipran (INN)
Milnacipran [INN]
Milnacipranum
Milnacipranum [Latin]
Milnacipranum [latin]
NCGC00165825-01
Toledomin
UNII-G56VK1HF36
milnacipran
7
Guanfacineapproved, investigationalPhase 45929110-47-23519
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
GUANFACINE
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine (INN)
Guanfacine Monohydrochloride
Guanfacine [INN:BAN]
Guanfacinum
 
Guanfacinum [INN-Latin]
Intuniv
L000286
L013430
LS-174236
Lon798
Lopac-G-1043
Lopac0_000519
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
8
Acetylcysteineapproved, investigationalPhase 4, Phase 2330616-91-112035
Synonyms:
(2R)-2-acetylamino-3-sulfanylpropanoic acid
(R)-2-acetylamino-3-mercaptopropanoic acid
(R)-mercapturic acid
2-Acetylamino-3-mercapto-propionate
2-Acetylamino-3-mercapto-propionic acid
ACC
Acetadote
Acetilcisteina
Acetylcysteine
Acetylcysteinum
Fluimicil Infantil
Fluimucetin
Fluimucil
Flumucetin
Fluprowit
 
L-Acetylcysteine
L-acetylcysteine
L-α-acetamido-β-mercaptopropionic acid
Lysox
Mercapturic acid
Mucolysin
Mucomyst
N-Acety-L-Cysteine
N-Acetyl-3-mercaptoalanine
N-Acetyl-L-(+)-cysteine
N-Acetylcysteine
N-acetyl-L-(+)-cysteine
N-acetyl-L-cysteine
N-acetylcysteine
NAC
Parvolex
Sodium 2-acetamido-3-mercaptopropionate
9
MetforminapprovedPhase 4, Phase 31803657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
10
Olanzapineapproved, investigationalPhase 4, Phase 2399132539-06-14585
Synonyms:
132539-06-1
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC-665
AC1L1IHS
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
LS-152313
LY 170053
LY-170052
 
LY-170053
Lanzac
Lilly brand of olanzapine
MLS000759457
MLS001165781
MLS001195646
MLS001424057
Midax
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
Olanzapina
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa Zydis
olanzapina
olanzapine
olanzapinum
11
ZiprasidoneapprovedPhase 4, Phase 3, Phase 2145146939-27-760854
Synonyms:
138982-67-9 (hydrochloride monohydrate)
146939-27-7
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one
5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one
5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one
6-chloro-5-[2-[4-(7-thia-8-azabicyclo[4.3.0]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one
AC1L1U27
Ambap122883-93-6
BIDD:GT0042
C07568
C21H21ClN4OS
CHEBI:10119
CHEMBL708
CID60854
CP 88059
CP 88059-01
CP-88,059
CP-88,059-01
CP-88,059-1
CP-88059-1
CPD000466328
D08687
DB00246
 
Geodon
Geodon Oral
I14-0766
L000659
LS-83744
MLS000759435
MolPort-003-850-885
SAM001246607
SMR000466328
TL8000889
UNII-6UKA5VEJ6X
Zeldox
Zipradon
Zipradon (TN)
Ziprasidona
Ziprasidone
Ziprasidone (INN)
Ziprasidone [INN:BAN]
Ziprasidone hydrochloride
Ziprasidone mesylate trihydrate
Ziprasidonum
ziprasidona
ziprasidonum
ziprazidone
12
DonepezilapprovedPhase 4, Phase 1, Phase 2286120014-06-43152
Synonyms:
( inverted exclamation markA)-E 2020
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
120014-06-4
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC-6969
AC1L1FAE
AKOS000277311
Aricept
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
 
Donepezil
Donepezil (INN)
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum5_001662
Spectrum_001664
TL8000531
UNII-8SSC91326P
13
Risperidoneapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1492106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
 
NCGC00015883-01
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
14
AcetylcholineapprovedPhase 4, Phase 180551-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
15
Melatoninapproved, nutraceutical, vet_approvedPhase 4, Phase 2, Phase 3, Phase 126873-31-4896
Synonyms:
0E2B08C1-B325-45B1-8939-6F9081EFDFA4
4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID
5-22-12-00042 (Beilstein Handbook Reference)
5-Methoxy-N-acetyltryptamine
5-methoxy-N-acetyltryptamine
73-31-4
A4039/0172195
AB00053279
AC1L1A9Q
AC1Q4F1W
AC1Q4F1X
AKOS000276269
Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI)
Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI)
Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI)
Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}
Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}
BAS 01281092
BIDD:ER0618
BPBio1_000590
BRD-K97530723-001-07-6
BRN 0205542
BSPBio_000536
BSPBio_003006
Bio-0635
C01598
CAS-73-31-4
CCRIS 3472
CHEBI:16796
CHEMBL45
CID896
ChemDiv2_003916
Circadin
D008550
D08170
DB01065
DB08189
DivK1c_000353
EINECS 200-797-7
EU-0100787
HMS1380B22
HMS1569K18
HMS1921E04
HMS2089F09
HMS501B15
HSCI1_000400
HSDB 7509
I05-0076
I10-0345
IDI1_000353
IDI1_002631
IN1244
KBio1_000353
KBio2_000665
KBio2_003233
KBio2_005801
KBio3_002226
KBioGR_000591
KBioSS_000665
L001261
LS-1623
Lopac-M-5250
Lopac0_000787
M 5250
M-1200
M-1250
M1105
M5250_SIGMA
ML1
MLS000859594
MLS001055382
MLS001240204
MT6
Mela-T
Melapure
Melatol
Melatonex
Melatonex, Melatonin
Melatonin
Melatonin (synth.) standard-grade
 
Melatonin (synth.) ultra-pure
Melatonina
Melatonina (TN)
Melatonine
Melovine
MolPort-000-737-883
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-Acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine Melatonine
N-Acetyl-5-methoxytryptamine
N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
N-acetyl-5-methoxy-tryptamine
NCGC00015680-01
NCGC00015680-02
NCGC00015680-03
NCGC00015680-06
NCGC00015680-13
NCGC00090727-01
NCGC00090727-02
NCGC00090727-03
NCGC00090727-04
NCGC00090727-05
NCGC00090727-06
NCGC00090727-07
NCGC00090727-08
NCGC00090727-09
NCI60_004378
NINDS_000353
NMR/14327425
NSC 113928
NSC113928
NSC56423
Nature'S Harmony
Night Rest
Oprea1_104553
Oprea1_814234
PREVENTION 1 (MELATONIN) (PREVENTION 1)
PREVENTION 2 (MELATONIN)
PREVENTION 3 (MELATONIN)
PREVENTION 4 (MELATONIN)
PREVENTION 5 (MELATONIN)
Pineal Hormone
Posidorm
Prestwick0_000458
Prestwick1_000458
Prestwick2_000458
Prestwick3_000458
Prestwick_312
Regulin
Revital Melatonin
Rx Balance
S1204_Selleck
SDCCGMLS-0065812.P001
SDCCGMLS-0065812.P002
SMP2_000309
SMR000326666
SPBio_001527
SPBio_002475
SPECTRUM1500690
STK386880
Sleep Right
Spectrum2_001344
Spectrum3_001393
Spectrum4_000066
Spectrum5_001745
Spectrum_000185
TNP00300
UNII-JL5DK93RCL
Vivitas
WLN: T56 BMJ D2MV1 GO1
ZINC00057060
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} Acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} Acetamide
16
Cholineapproved, nutraceuticalPhase 415462-49-7305
Synonyms:
(2-Hydroxyethyl)trimethyl ammonium
(2-Hydroxyethyl)trimethylammonium
(beta-hydroxyethyl)trimethylammonium
2-Hydroxy-N,N,N-trimethyl-ethanaminium
2-Hydroxy-N,N,N-trimethylethanaminium
Bilineurine
Biocolina
Biocoline
Choline
Choline cation
 
Choline ion
Cholinum
Hepacholine
Hormocline
Lipotril
N,N,N-Trimethylethanol-ammonium
N,N,N-Trimethylethanolammonium
N,N,N-trimethylethanol-ammonium
N-trimethylethanolamine
Neocolina
Paresan
trimethylethanolamine
17Central Nervous System StimulantsPhase 4, Phase 3, Phase 2, Phase 12211
18Cholinergic AgentsPhase 4, Phase 3, Phase 2, Phase 13992
19Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 1, Phase 223689
20Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 122062
21Antiviral AgentsPhase 4, Phase 29967
22Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18402
23Dopamine Uptake InhibitorsPhase 4, Phase 3, Phase 21331
24Respiratory System AgentsPhase 4, Phase 2, Phase 34997
25ImmunoglobulinsPhase 4, Phase 26394
26Immunoglobulins, IntravenousPhase 4, Phase 2333
27Rho(D) Immune GlobulinPhase 4, Phase 2326
28OxytocicsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1707
29gamma-GlobulinsPhase 4, Phase 2326
30AntibodiesPhase 4, Phase 26394
31Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Phase 113403
32Pharmaceutical SolutionsPhase 4, Phase 3, Phase 2, Early Phase 18192
33Psychotropic DrugsPhase 4, Phase 3, Phase 2, Phase 16430
34Tranquilizing AgentsPhase 4, Phase 3, Phase 2, Phase 14265
35Dopamine AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 13836
36Antiparkinson AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11574
37Antipsychotic AgentsPhase 4, Phase 3, Phase 2, Phase 12401
38Adrenergic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15352
39Neurotransmitter Uptake InhibitorsPhase 4, Phase 3, Phase 2, Phase 13521
40Neurotransmitter AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 118340
41Excitatory Amino AcidsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 11362
42Excitatory Amino Acid AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 11347
43AntidotesPhase 4, Phase 3, Phase 21071
44Protective AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 17443
45Cholinesterase InhibitorsPhase 4, Phase 3, Phase 1, Phase 2592
46Vasodilator AgentsPhase 4, Phase 2, Early Phase 13543
47AntioxidantsPhase 4, Phase 2, Phase 3, Phase 13050
48N-monoacetylcystinePhase 4, Phase 2330
49ExpectorantsPhase 4, Phase 2404
50Nootropic AgentsPhase 4, Phase 3, Phase 1, Phase 2716

Interventional clinical trials:

(show top 50)    (show all 593)
idNameStatusNCT IDPhase
1Study to Evaluate the Efficacy and Safety of AripiprazoleUnknown statusNCT02069977Phase 4
2An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism SpectrumUnknown statusNCT02199925Phase 4
3A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum DisordersCompletedNCT01333865Phase 4
4FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum DisordersCompletedNCT01028820Phase 4
5Omega-3 Fatty Acids in Autism Spectrum DisordersCompletedNCT01695200Phase 4
6Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum DisorderCompletedNCT00380692Phase 4
7Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental DisorderCompletedNCT01238575Phase 4
8Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot StudyCompletedNCT02255565Phase 4
9Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With AutismCompletedNCT02235467Phase 4
10Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of AutismCompletedNCT01337700Phase 4
11Atomoxetine, Placebo and Parent Management Training in AutismCompletedNCT00844753Phase 4
12A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASDCompletedNCT00485849Phase 4
13An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.CompletedNCT00391261Phase 4
14Metabolic Effects of Antipsychotics in ChildrenCompletedNCT00205699Phase 4
15A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in ChildrenCompletedNCT01050582Phase 4
16Methylphenidate ER Liquid Formulation in Adults With ASD and ADHDRecruitingNCT02096952Phase 4
17Gut to Brain Interaction in Autism. Role of Probiotics on Clinical, Biochemical and Neurophysiological ParametersRecruitingNCT02708901Phase 4
18Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum DisordersRecruitingNCT01098383Phase 4
19The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage SchizophreniaActive, not recruitingNCT01339858Phase 4
20Neural and Behavioral Effects of Oxytocin in Autism Spectrum DisordersEnrolling by invitationNCT02940574Phase 4
21Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum DisordersTerminatedNCT01033565Phase 4
221/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight GainTerminatedNCT01844700Phase 4
23Oxytocin in Adolescents With Autism Spectrum DisordersUnknown statusNCT02007447Phase 2, Phase 3
24Group Psychoeducational Program for Mothers of Children With High Functional Pervasive Developmental DisordersUnknown statusNCT01243905Phase 2, Phase 3
25Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum DisordersCompletedNCT02081027Phase 2, Phase 3
26Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)CompletedNCT01825798Phase 3
27Understanding Sleep Problems in Children With Autism Spectrum DisorderCompletedNCT00691080Phase 2, Phase 3
28D-Cycloserine and Social Skills Training in Autism Spectrum DisordersCompletedNCT01086475Phase 3
29Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum DisordersCompletedNCT01178385Phase 2, Phase 3
30Study of Aripiprazole in the Treatment of Pervasive Developmental DisordersCompletedNCT00870727Phase 3
31Acamprosate in Youth With Fragile X SyndromeCompletedNCT01300923Phase 3
32Supporting the Well Being of Families of Young Children With Autism Spectrum DisordersCompletedNCT01021384Phase 3
33Use of Acupuncture In Children With Autistic Spectrum DisorderCompletedNCT00346736Phase 3
34Use of Acupuncture In Children With Autistic Spectrum DisorderCompletedNCT00352352Phase 3
35A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)CompletedNCT00261508Phase 3
36Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum DisorderCompletedNCT00352248Phase 3
37Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical CorrelationCompletedNCT00355329Phase 3
38A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) SymptomsCompletedNCT00541346Phase 3
39Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With AutismCompletedNCT00498173Phase 3
40Pharmacogenomics in Autism TreatmentCompletedNCT00584701Phase 2, Phase 3
41Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in ChildrenCompletedNCT00178503Phase 2, Phase 3
42Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X SyndromeCompletedNCT01282268Phase 3
43Open Label Clinical Trial of Vitamin D in Children With AutismCompletedNCT01535508Phase 2, Phase 3
44Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With AutismCompletedNCT01039792Phase 2, Phase 3
45Galantamine Versus Placebo in Childhood AutismCompletedNCT00252603Phase 3
46Study of Paliperidone ER in Adolescents and Young Adults With AutismCompletedNCT00549562Phase 3
47Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.CompletedNCT00399698Phase 3
48Secretin for the Treatment of AutismCompletedNCT00065962Phase 3
49Lurasidone Pediatric Autism StudyCompletedNCT01911442Phase 3
50Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)CompletedNCT00365859Phase 3

Search NIH Clinical Center for Autism Spectrum Disorder

Genetic Tests for Autism Spectrum Disorder

About this section

Genetic tests related to Autism Spectrum Disorder:

id Genetic test Affiliating Genes
1 Autism Spectrum Disorders27 24 NLGN3, NLGN4X, RPL10, SHANK2, SHANK3, SNRPN

Anatomical Context for Autism Spectrum Disorder

About this section

MalaCards organs/tissues related to Autism Spectrum Disorder:

36
Brain, Eye, Testes, Cortex, Amygdala, Skin, Cerebellum

Publications for Autism Spectrum Disorder

About this section

Articles related to Autism Spectrum Disorder:

(show top 50)    (show all 1088)
idTitleAuthorsYear
1
Serum levels of Glial fibrillary acidic protein in Chinese children with autism spectrum disorders. (28088366)
2017
2
Bone microarchitecture in adolescent boys with autism spectrum disorder. (28088646)
2017
3
Modified-Release Methylphenidate-Related Trichotillomania in a Boy with Autism Spectrum Disorder. (28394174)
2017
4
Emotion Regulation and Parent Co-Regulation in Children with Autism Spectrum Disorder. (28070784)
2017
5
Social and Non-social Hazard Response in Drivers with Autism Spectrum Disorder. (28070791)
2017
6
I8-3 Fatty Acid Supplementation Does Not Affect Autism Spectrum Disorder in Children: A Systematic Review and Meta-Analysis. (28077731)
2017
7
Brief Report: Mealtime Behaviors of Chinese American Children with Autism Spectrum Disorder. (28070790)
2017
8
Dietary adequacy of Egyptian children with autism spectrum disorder compared to healthy developing children. (28074329)
2017
9
Improving Early Identification and Intervention for Children at Risk for Autism Spectrum Disorder. (28082407)
2017
10
Health Care Transition Planning Among Adolescents with Autism Spectrum Disorder. (28078534)
2017
11
Self-injurious behaviour in people with intellectual disability and autism spectrum disorder. (28030375)
2017
12
Predictors of Self-Injurious Behavior and Self-Restraint in Autism Spectrum Disorder: Towards a Hypothesis of Impaired Behavioral Control. (28070787)
2017
13
Training Parents of Youth with Autism Spectrum Disorder to Advocate for Adult Disability Services: Results from a Pilot Randomized Controlled Trial. (28070786)
2017
14
Advances in developmental neuropsychiatry: autism spectrum disorder, Cornelia De Lange syndrome, self-injurious behavior, Down syndrome, fetal alcohol spectrum disorder, and borderline intellectual functioning. (28067728)
2017
15
Opposing Effects on NaV1.2 Function Underlie Differences Between SCN2A Variants Observed in Individuals With Autism Spectrum Disorder or Infantile Seizures. (28256214)
2017
16
Age-related differences in prevalence of autism spectrum disorder symptoms in children and adolescents with Costello syndrome. (28374929)
2017
17
Disruptive behaviour may hinder the acquisition of daily living skills for youth with autism spectrum disorder. (28087560)
2017
18
Cognitive profiles of adults with high-functioning autism spectrum disorder and those with attention-deficit/hyperactivity disorder based on the WAIS-III. (28064024)
2017
19
Language Skills of Males with Fragile X Syndrome or Nonsyndromic Autism Spectrum Disorder. (28074353)
2017
20
Elizabeth Usher Memorial Lecture: Rethinking the clinical pathway for autism spectrum disorder and challenging the status quo. (28084105)
2017
21
Test of Gross Motor Development-3 (TGMD-3) with the Use of Visual Supports for Children with Autism Spectrum Disorder: Validity and Reliability. (28091840)
2017
22
Language ENvironment Analysis (LENA) in Phelan-McDermid Syndrome: Validity and Suggestions for Use in Minimally Verbal Children with Autism Spectrum Disorder. (28255759)
2017
23
Beyond the hype and hope: Critical considerations for intranasal oxytocin research in autism spectrum disorder. (27651096)
2016
24
Persistence of megalencephaly in a subgroup of young boys with autism spectrum disorder. (27273931)
2016
25
Succinic Semialdehyde Dehydrogenase Deficiency Presenting as Autism Spectrum Disorder. (26806207)
2016
26
The Social Feedback Hypothesis and Communicative Development in Autism Spectrum Disorder: A Response to Akhtar, Jaswal, Dinishak, and Stephan (2016). (27664191)
2016
27
Narratives of children with high-functioning autism spectrum disorder: A meta-analysis. (27643571)
2016
28
Finding novel distinctions between the sAPPI+-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue. (27212113)
2016
29
Reported Wandering Behavior among Children with Autism Spectrum Disorder and/or Intellectual Disability. (27157446)
2016
30
Xq11.1-11.2 deletion involving ARHGEF9 in a girl with autism spectrum disorder. (27238888)
2016
31
Correlation between Nutrition and Symptoms: Nutritional Survey of Children with Autism Spectrum Disorder in Chongqing, China. (27187463)
2016
32
Sleep Disorder, Gastrointestinal Problems and Behaviour Problems Seen in Autism Spectrum Disorder Children and Yoga as Therapy: A Descriptive Review. (28050484)
2016
33
Testosterone and Androgen Receptor Sensitivity in Relation to Hyperactivity Symptoms in Boys with Autism Spectrum Disorders. (26910733)
2016
34
Callous unemotional traits, autism spectrum disorder symptoms and empathy in boys with oppositional defiant disorder or conduct disorder. (27575651)
2016
35
Overlapping Phenotypes in Autism Spectrum Disorder and Developmental Coordination Disorder: A Cross-Syndrome Comparison of Motor and Social Skills. (27126816)
2016
36
Default mode network abnormalities in children with autism spectrum disorder detected by resting-state functional magnetic resonance imaging. (27644559)
2016
37
Impaired downregulation of visual cortex during auditory processing is associated with autism symptomatology in children and adolescents with autism spectrum disorder. (27205875)
2016
38
Spillover of Marital Interactions and Parenting Stress in Families of Children With Autism Spectrum Disorder. (27218268)
2016
39
Genome-wide analysis of copy number variations identifies PARK2 as a candidate gene for autism spectrum disorder. (27042285)
2016
40
PX-RICS-deficient mice mimic autism spectrum disorder in Jacobsen syndrome through impaired GABAA receptor trafficking. (26979507)
2016
41
Clinical trial of modulatory effects of oxytocin treatment on higher-order social cognition in autism spectrum disorder: a randomized, placebo-controlled, double-blind and crossover trial. (27655235)
2016
42
Coexistence of Autism Spectrum Disorders Among Three Children with Tuberous Sclerosis Complex: Case reports and review of literature. (28003905)
2016
43
Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders. (26872113)
2016
44
Characterizing Objective Quality of Life and Normative Outcomes in Adults with Autism Spectrum Disorder: An Exploratory Latent Class Analysis. (27207091)
2016
45
Elevated levels of tissue plasminogen activator and E-selectin in male children with autism spectrum disorder. (27194368)
2016
46
Different brain responses during empathy in autism spectrum disorders versus conduct disorder and callous-unemotional traits. (26681358)
2016
47
CHD8 intragenic deletion associated with autism spectrum disorder. (26921529)
2016
48
Autism spectrum disorder in the scope of tactile processing. (28089657)
2016
49
Predicting symptom severity in autism spectrum disorder based on cortical thickness measures in agglomerative data. (27664827)
2016
50
Comprehension of ambiguity for children with Specific Language Impairment and Autism Spectrum Disorder. (27982253)
2016

Variations for Autism Spectrum Disorder

About this section

Clinvar genetic disease variations for Autism Spectrum Disorder:

5 (show all 35)
id Gene Variation Type Significance SNP ID Assembly Location
1EHMT1NM_ 024757.4(EHMT1): c.3413G> A (p.Trp1138Ter)SNVPathogenicrs886037776GRCh37Chr 9, 140711929: 140711929
2ACR; ARSA; MAPK8IP2; RABL2B; SHANK3NC_ 000022.10: g.(?_ 51027581)_ (51234443_ ?)deldeletionPathogenicGRCh37Chr 22, 51027581: 51234443
3subset of 35 genes:SHANK3NC_ 000022.10: g.(?_ 50282986)_ (51304566_ ?)deldeletionPathogenicGRCh37Chr 22, 50282986: 51304566
4subset of 36 genes:SHANK3NC_ 000022.10: g.(?_ 49033233)_ (51193680_ ?)deldeletionPathogenicGRCh37Chr 22, 49033233: 51193680
5NC_ 000015.8: g.26762141_ 30302218del3540078deletionPathogenicNCBI36Chr 15, 26762141: 30302218
6NC_ 000005.8: g.175492445_ 177359136del1866692deletionPathogenicNCBI36Chr 5, 175492445: 177359136
7NC_ 000015.8: g.28723577_ 30322604del1599028deletionPathogenicNCBI36Chr 15, 28723577: 30322604
8NC_ 000015.8: g.21200233_ 26762141dup5561909duplicationPathogenicNCBI36Chr 15, 21200233: 26762141
9NC_ 000015.8: g.19359417_ 26208861dup6849445duplicationPathogenicNCBI36Chr 15, 19359417: 26208861
10NC_ 000015.8: g.19359417_ 30302218del10942802deletionPathogenicNCBI36Chr 15, 19359417: 30302218
11NC_ 000001.9: g.144967972_ 146293282dup1325311duplicationPathogenicNCBI36Chr 1, 144967972: 146293282
12NC_ 000001.9: g.144943150_ 146293282del1350133deletionPathogenicNCBI36Chr 1, 144943150: 146293282
13NC_ 000001.9: g.144970465_ 146293282dup1322818duplicationPathogenicNCBI36Chr 1, 144970465: 146293282
14NC_ 000001.9: g.145119261_ 146293282dup1174022duplicationPathogenicNCBI36Chr 1, 145119261: 146293282
15NC_ 000016.8: g.29554843_ 30085308del530466deletionPathogenicNCBI36Chr 16, 29554843: 30085308
16NC_ 000016.8: g.29554843_ 30085308dup530466duplicationPathogenicNCBI36Chr 16, 29554843: 30085308
17NC_ 000017.9: g.14040467_ 15411904del1371438deletionPathogenicNCBI36Chr 17, 14040467: 15411904
18NC_ 000017.9: g.14040467_ 15411904dup1371438duplicationPathogenicNCBI36Chr 17, 14040467: 15411904
19NC_ 000017.9: g.14039002_ 15411904dup1372903duplicationPathogenicNCBI36Chr 17, 14039002: 15411904
20NC_ 000022.9: g.17257787_ 18686993dup1429207duplicationPathogenicNCBI36Chr 22, 17257787: 18686993
21NC_ 000022.9: g.17257787_ 19792353dup2534567duplicationPathogenicNCBI36Chr 22, 17257787: 19792353
22NC_ 000022.9: g.17266915_ 21751058dup4484144duplicationPathogenicNCBI36Chr 22, 17266915: 21751058
23NC_ 000022.9: g.21995356_ 23326630dup1331275duplicationPathogenicNCBI36Chr 22, 21995356: 23326630
24NC_ 000022.9: g.21309897_ 23340746dup2030850duplicationPathogenicNCBI36Chr 22, 21309897: 23340746
25CHRNA7; FAN1; KLF13; MIR211; MTMR10; OTUD7A; TRPM1NC_ 000015.9: g.30940504_ 32620088del1679585deletionPathogenicGRCh37Chr 15, 30940504: 32620088
26subset of 11 genes:UBE3ANC_ 000015.9: g.25334522_ 28369712dup3035191duplicationPathogenicGRCh37Chr 15, 25334522: 28369712
27subset of 30 genes:MAGEL2; SNURF; UBE3ANC_ 000015.9: g.20306549_ 26208861dup5902313duplicationPathogenicGRCh37Chr 15, 20306549: 26208861
28subset of 35 genes:MAGEL2; SNURF; UBE3ANC_ 000015.9: g.20044342_ 28924405dup8880064duplicationPathogenicGRCh37Chr 15, 20044342: 28924405
29subset of 24 genes:MAGEL2; SNURF; UBE3ANC_ 000015.9: g.23624148_ 28790734dup5166587duplicationPathogenicGRCh37Chr 15, 23624148: 28790734
30ACP6; BCL9; CHD1L; FMO5; GJA5; GJA8; GPR89B; HYDIN2; NBPF12; PRKAB2NC_ 000001.10: g.146089254_ 148004783dup1915530duplicationPathogenicGRCh37Chr 1, 146089254: 148004783
31ACP6; BCL9; CHD1L; FMO5; GJA5; GJA8; GPR89B; PRKAB2NC_ 000001.10: g.146499479_ 147830375dup1330897duplicationPathogenicGRCh37Chr 1, 146499479: 147830375
32CDRT15; CDRT4; COX10; HS3ST3B1; PMP22; TEKT3; TVP23C; TVP23C-CDRT4NC_ 000017.10: g.14101029_ 15482817del1381789deletionPathogenicGRCh37Chr 17, 14101029: 15482817
33subset of 15 genes:HNF1BNC_ 000017.10: g.34815551_ 36249800dup1434250duplicationPathogenicGRCh37Chr 17, 34815551: 36249800
34subset of 39 genes:TBX1NC_ 000022.10: g.18874965_ 21028946dup2153982duplicationPathogenicGRCh37Chr 22, 18874965: 21028946
35subset of 27 genes:ELNNC_ 000007.13: g.72718278_ 74140708dup1422431duplicationPathogenicGRCh37Chr 7, 72718278: 74140708

Expression for genes affiliated with Autism Spectrum Disorder

About this section
Search GEO for disease gene expression data for Autism Spectrum Disorder.

Pathways for genes affiliated with Autism Spectrum Disorder

About this section

GO Terms for genes affiliated with Autism Spectrum Disorder

About this section

Cellular components related to Autism Spectrum Disorder according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1excitatory synapseGO:006007611.2NLGN3, NLGN4X, SHANK1
2dendritic spineGO:004319711.2FMR1, SHANK1, SHANK2, SHANK3
3ionotropic glutamate receptor complexGO:000832811.2SHANK1, SHANK2
4cell junctionGO:003005411.2FMR1, NLGN3, NLGN4X, NRXN1, SHANK1, SHANK2
5postsynapseGO:009879411.1FMR1, MECP2, NLGN3
6neuron projectionGO:004300511.1FMR1, SHANK1, SHANK2, SHANK3, SLC6A4
7postsynaptic densityGO:001406911.1FMR1, NLGN4X, SHANK1, SHANK2, SHANK3
8integral component of plasma membraneGO:000588711.1NLGN3, NLGN4X, NRXN1, NRXN3, OXTR, SCN2A
9postsynaptic membraneGO:004521111.1FMR1, NLGN4X, SHANK1, SHANK2, SHANK3
10presynapseGO:009879311.1FMR1, NRXN3, SLC6A4
11synapseGO:004520210.4FMR1, NLGN3, NLGN4X, NRXN1, SHANK1, SHANK2

Biological processes related to Autism Spectrum Disorder according to GeneCards Suite gene sharing:

(show all 41)
idNameGO IDScoreTop Affiliating Genes
1brain morphogenesisGO:004885411.2SHANK3, SLC6A4
2exploration behaviorGO:003564011.2SHANK2, SHANK3
3dendritic spine morphogenesisGO:006099711.2SHANK1, SHANK3
4long term synaptic depressionGO:006029211.1SHANK2, SHANK3
5histone methylationGO:001657111.1EHMT1, MECP2
6guanylate kinase-associated protein clusteringGO:009711711.1NRXN1, SHANK3
7adult behaviorGO:003053411.1CNTNAP2, NLGN3, NLGN4X, NRXN1, NRXN3, SHANK1
8brain developmentGO:000742011.1CHD8, CNTNAP2, MECP2, SLC6A4
9negative regulation of excitatory postsynaptic potentialGO:009039411.1NLGN3, NLGN4X
10inositol metabolic processGO:000602011.1MECP2, PPIP5K2
11negative regulation of actin filament bundle assemblyGO:003223211.1SHANK1, SHANK3
12long-term synaptic potentiationGO:006029111.1MECP2, NLGN3, SHANK2, SHANK3
13cell adhesionGO:000715511.1CNTNAP2, NLGN3, NLGN4X, NRXN1, NRXN3
14neuromuscular process controlling balanceGO:005088511.1NRXN1, SHANK1, SHANK3
15positive regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activityGO:200096911.1NLGN3, SHANK3
16neuron cell-cell adhesionGO:000715811.1NLGN3, NLGN4X, NRXN1, NRXN3
17NMDA glutamate receptor clusteringGO:009711411.1NRXN1, SHANK3
18memoryGO:000761311.1MECP2, OXTR, SHANK2, SHANK3, SLC6A4
19neuron differentiationGO:003018211.1MECP2, MYT1L, NLGN4X
20learningGO:000761211.1CNTNAP2, MECP2, NLGN3, NLGN4X, NRXN1, NRXN3
21positive regulation of dendritic spine developmentGO:006099911.1FMR1, SHANK1, SHANK3
22positive regulation of excitatory postsynaptic potentialGO:200046311.1NLGN3, NRXN1, SHANK1, SHANK3
23positive regulation of synapse maturationGO:009012911.1NRXN1, NRXN3
24postsynaptic membrane assemblyGO:009710411.1NLGN3, NRXN1
25regulation of dendritic spine morphogenesisGO:006100111.1NLGN3, SHANK3
26presynaptic membrane assemblyGO:009710511.1NLGN3, NLGN4X, NRXN1
27regulation of long-term synaptic potentiationGO:190027111.1NLGN3, SHANK3
28protein localization to synapseGO:003541811.0NRXN1, SHANK1
29regulation of grooming behaviorGO:200082111.0NRXN1, SHANK3
30positive regulation of synaptic transmission, glutamatergicGO:005196811.0NLGN3, NRXN1, OXTR, SHANK2, SHANK3
31regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activityGO:200031111.0NLGN3, NRXN1, SHANK1
32regulation of N-methyl-D-aspartate selective glutamate receptor activityGO:200031011.0NLGN3, NRXN1
33positive regulation of synapse assemblyGO:005196511.0MECP2, NLGN3, NRXN1, NRXN3, OXTR
34regulation of respiratory gaseous exchange by neurological system processGO:000208711.0MECP2, NLGN3
35righting reflexGO:006001311.0AUTS2, SHANK1
36sperm ejaculationGO:004271311.0OXTR, SLC6A4
37social behaviorGO:003517610.9CNTNAP2, MECP2, NLGN3, NLGN4X, NRXN1, NRXN3
38synapse assemblyGO:000741610.8MECP2, NLGN3, NRXN1, NRXN3, SHANK2, SHANK3
39thalamus developmentGO:002179410.8CNTNAP2, SLC6A4
40vocal learningGO:004229710.7CNTNAP2, NRXN1, SHANK3
41vocalization behaviorGO:007162510.4CNTNAP2, NLGN3, NLGN4X, NRXN1, NRXN3, SHANK1

Molecular functions related to Autism Spectrum Disorder according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1GKAP/Homer scaffold activityGO:003016011.1SHANK1, SHANK2, SHANK3
2neurexin family protein bindingGO:004204311.1NLGN3, NLGN4X
3ionotropic glutamate receptor bindingGO:003525511.1SHANK1, SHANK2, SHANK3
4neuroligin family protein bindingGO:009710911.1NRXN1, NRXN3
5cell adhesion molecule bindingGO:005083911.1NLGN3, NLGN4X, NRXN1, NRXN3
6receptor activityGO:000487211.0NLGN3, NLGN4X, NRXN1, NRXN3
7scaffold protein bindingGO:009711011.0NLGN3, NLGN4X, SHANK1, SHANK3
8SH3 domain bindingGO:001712410.7SHANK1, SHANK2, SHANK3
9siRNA bindingGO:003519710.4FMR1, MECP2

Sources for Autism Spectrum Disorder

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet